Literature DB >> 22929875

Homelessness in schizophrenia.

Adriana Foster1, James Gable, John Buckley.   

Abstract

The impact of mental illness, comorbid substance abuse, and medication nonadherence, coupled with disjointed psychiatric and social services, conspires to a disproportionately high rate of psychiatric disorders among people who are homeless in the United States. This article reviews the prevalence of homeless among the mentally ill as well as the prevalence of mental illness among the homeless and details barriers in access to care and the solutions that have been attempted. The need and solutions to introduce a new generation of physicians and allied health care workers to the unique health care needs of the homeless population are highlighted.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22929875     DOI: 10.1016/j.psc.2012.06.010

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  16 in total

1.  A 6-Month Prospective Trial of a Personalized Behavioral Intervention + Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk of Treatment Nonadherence and Homelessness.

Authors:  Martha Sajatovic; Luis F Ramirez; Edna Fuentes-Casiano; Jamie Cage; Curtis Tatsuoka; Michelle E Aebi; Ashley Bukach; Kristin A Cassidy; Jennifer B Levin
Journal:  J Clin Psychopharmacol       Date:  2017-12       Impact factor: 3.153

2.  A cross sectional study of prevalence and correlates of current and past risks in schizophrenia.

Authors:  Kiran Jakhar; Triptish Bhatia; Rahul Saha; Smita N Deshpande
Journal:  Asian J Psychiatr       Date:  2015-02-03

3.  Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.

Authors:  Martha Sajatovic; Jennifer Levin; Luis F Ramirez; David Y Hahn; Curtis Tatsuoka; Christopher S Bialko; Kristin A Cassidy; Edna Fuentes-Casiano; Tiffany D Williams
Journal:  J Clin Psychiatry       Date:  2013-12       Impact factor: 4.384

4.  Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects.

Authors:  Albert T Higgins-Chen; Marco P Boks; Christiaan H Vinkers; René S Kahn; Morgan E Levine
Journal:  Biol Psychiatry       Date:  2020-02-08       Impact factor: 13.382

5.  Providing Effective Primary Care for Patients with Serious Mental Illness: Additional Components to Enhance Practice.

Authors:  Beat Daniel Steiner; Jack Todd Wahrenberger; Lori Raney
Journal:  Community Ment Health J       Date:  2019-12-12

6.  The impact of a short-term cohousing initiative among schizophrenia patients, high school students, and their social context: A qualitative case study.

Authors:  Domingo Palacios-Ceña; Emilio Andrés Martín-Tejedor; Ana Elías-Elispuru; Amaia Garate-Samaniego; Jorge Pérez-Corrales; Elena García-García
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

Review 7.  The Importance of Non-neuronal Cell Types in hiPSC-Based Disease Modeling and Drug Screening.

Authors:  David M Gonzalez; Jill Gregory; Kristen J Brennand
Journal:  Front Cell Dev Biol       Date:  2017-12-19

Review 8.  Potential Value of Genomic Copy Number Variations in Schizophrenia.

Authors:  Chuanjun Zhuo; Weihong Hou; Chongguang Lin; Lirong Hu; Jie Li
Journal:  Front Mol Neurosci       Date:  2017-06-21       Impact factor: 5.639

9.  Family reintegration of homeless in Maputo and Matola: a descriptive study.

Authors:  Lídia Gouveia; Honório Massanganhe; Flávio Mandlate; Dirceu Mabunda; Wilza Fumo; Ana Olga Mocumbi; Jair de Jesus Mari
Journal:  Int J Ment Health Syst       Date:  2017-04-11

10.  A Bayesian Approach to Modeling Risk of Hospital Admissions Associated With Schizophrenia Accounting for Underdiagnosis of the Disorder in Administrative Records.

Authors:  Eileen M Stock; James D Stamey; John E Zeber; Alexander W Thompson; Laurel A Copeland
Journal:  Comput Psychiatr       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.